HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and
clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and
preliminary anti-tumor efficacy of HLX301 administered as a single-agent by IV infusion every
2 weeks to patients with locally advanced or metastatic solid malignancies, who have failed
or are intolerant to standard therapy, or for whom no standard therapy is available. This
study has three parts: phase 1a dose escalation, phase 1b dose expansion, and phase 2
clinical expansion.